Comparison 3. Anticoagulants versus control: symptomatic pulmonary embolism.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Symptomatic PE: DOAC vs placebo	3	1526	Risk Ratio (IV, Random, 95% CI)	0.38 [0.10, 1.47]
3.1.1 Apixaban	2	685	Risk Ratio (IV, Random, 95% CI)	0.17 [0.04, 0.67]
3.1.2 Rivaroxaban	1	841	Risk Ratio (IV, Random, 95% CI)	1.00 [0.29, 3.44]
3.2 Symptomatic PE: LMWH vs no thromboprophylaxis	8	5324	Risk Ratio (IV, Random, 95% CI)	0.60 [0.42, 0.88]
3.2.1 Dalteparin	5	2979	Risk Ratio (IV, Random, 95% CI)	0.63 [0.42, 0.94]
3.2.2 Nadroparin	1	1150	Risk Ratio (IV, Random, 95% CI)	0.50 [0.10, 2.44]
3.2.3 Certoparin	1	883	Risk Ratio (IV, Random, 95% CI)	0.60 [0.14, 2.49]
3.2.4 Enoxaparin	1	312	Risk Ratio (IV, Random, 95% CI)	0.14 [0.01, 2.61]
3.3 Symptomatic PE: prophylactic vs intermediate or therapeutic LMWH	1		Risk Ratio (IV, Fixed, 95% CI)	Subtotals only
3.3.1 Prophylactic vs intermediate	1	51	Risk Ratio (IV, Fixed, 95% CI)	2.89 [0.12, 67.75]
3.3.2 Prophylactic vs therapeutic	1	52	Risk Ratio (IV, Fixed, 95% CI)	3.00 [0.13, 70.42]
3.4 Symptomatic PE: LMWH vs aspirin	2	781	Risk Ratio (IV, Random, 95% CI)	0.13 [0.02, 1.03]
3.5 Symptomatic PE: LMWH vs warfarin	1	439	Risk Ratio (IV, Fixed, 95% CI)	0.11 [0.01, 2.06]
3.6 Symptomatic PE: semuloparin vs placebo	1	3212	Risk Ratio (IV, Fixed, 95% CI)	0.48 [0.22, 1.01]
3.7 Symptomatic PE: vitamin K antagonists vs placebo	1	311	Risk Ratio (IV, Fixed, 95% CI)	1.05 [0.07, 16.58]
3.8 Symptomatic PE: warfarin vs aspirin	1	440	Risk Ratio (IV, Fixed, 95% CI)	1.00 [0.25, 3.95]